RhumbLine Advisers’s Neos Therapeutics, Inc NEOS Stock Holding History

RhumbLine Advisers’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-53,730	Closed	-$140K	–	3036
2019 Q1	$140K	Buy	53,730 +16,288	+44%	+$38.2K	﹤0.01%	2815
2018 Q4	$62K	Buy	37,442 +12,871	+52%	+$36.1K	﹤0.01%	2927
2018 Q3	$119K	Sell	24,571 -1,500	-6%	-$8.51K	﹤0.01%	2843
2018 Q2	$163K	Buy	26,071 +5,226	+25%	+$39K	﹤0.01%	2786
2018 Q1	$173K	Buy	20,845 +2,685	+15%	+$25.6K	﹤0.01%	2641
2017 Q4	$185K	Sell	18,160 -2,749	-13%	-$26.4K	﹤0.01%	2654
2017 Q3	$191K	Buy	20,909 +500	+2%	+$3.8K	﹤0.01%	2755
2017 Q2	$149K	Buy	20,409 +2,441	+14%	+$18.4K	﹤0.01%	2840
2017 Q1	$129K	Buy	17,968 +4,985	+38%	+$30.9K	﹤0.01%	2749
2016 Q4	$76K	Buy	12,983 +2,878	+28%	+$19.5K	﹤0.01%	2809
2016 Q3	$66K	Buy	+10,105	New	+$80.1K	﹤0.01%	2844

Other funds holding NEOS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's NEOS Position: Q2 2019 in Review

RhumbLine Advisers sold out of Neos Therapeutics, Inc (NEOS) in Q2 2019, closing a stake of 53,730 shares — an estimated $140K sold.

RhumbLine Advisers first reported a position in NEOS in Q3 2016 and held it in 11 quarters. The position peaked at $191K in Q3 2017. 58 funds tracked by Wall St. Rank hold NEOS as of Q2 2019.

RhumbLine Advisers reported no remaining Neos Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
RhumbLine Advisers sold 53,730 Neos Therapeutics, Inc shares in Q2 2019, an estimated $140K.
RhumbLine Advisers first reported a position in Neos Therapeutics, Inc in Q3 2016 and held it in 11 quarters.
RhumbLine Advisers's Neos Therapeutics, Inc position peaked at $191K in Q3 2017.
58 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q2 2019.

Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.